secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001493152-25-005536
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025
-----------------------------------------------------------------------------

- Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.
- Lead program IMNN-001 for advanced ovarian cancer on track to enter Phase 3 pivotal trial in Q1 2025.
- Compensation: $480k salary, 40% bonus target, inducement options for 100,000 shares with 4-year vesting.
- Dr. Faller brings 30+ years of oncology/immunology experience from Takeda, Skyhawk, and academic roles.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer